Eli Lilly & Co. (LLY) Tops Q4 EPS by 29c, Lifts Outlook

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.35 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2023 EPS of $8.35-$8.55, versus the consensus of $8.28. Eli Lilly & Co. sees FY2023 revenue of $30.3-30.8 billion, versus the consensus of $30.55 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• McCormick & Co. (MKC) Tops Q2 EPS by 10c ; Offers Guidance
• Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats